# US 2022/0023292 A1 · Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0023292 A1
- Document ID: US20220023292A1
- Status: Published application
- Kind: A1
- Application number: 17/181,976
- Filed: 2021-02-22
- Published: 2022-01-27
- Earliest claimed: 2008-10-30
- Assignees: Concert Pharmaceuticals, Inc.
- Applicants: Concert Pharmaceuticals, Inc.
- Inventors: Amanda Thomas
- Web page: https://patentgrep.com/patent/US20220023292A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.

## Claims

### Claim 1

A method of treating pseudobulbar affect in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of a co-agent selected from the grouping consisting of a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant; or pharmaceutically acceptable salts thereof, and a therapeutically effective amount of a compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
R3 is selected from —OCH3, —OCH2D, —OCHD2, —OCD3, —OCHF2, and —OCF3; and
R4 is selected from —CH3, —CH2D, —CHD2, and —CD3;
provided that when R3 is —OCH3, then R4 is not —CH3 or —CD3;
further provided that when R3 is —OCD3, then R4 is not —CH3.

### Claim 2 (depends on 1)

The method of claim 1, wherein R4 is —CH3, —CHD2, or —CD3.

### Claim 3 (depends on 2)

The method of claim 2, wherein R3 is —OCF3, —OCD3, or —OCHF2.

### Claim 4 (depends on 1)

The method of claim 1, wherein said co-agent is an inhibitor of a cytochrome p450 2D6 enzyme.

### Claim 5 (depends on 1)

The method of claim 1, wherein said co-agent is selected from the group consisting of a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; norfluoxetine, citalopram, dapoxetine, escitalopram, fluvoxamine, paroxetine, sertraline, butriptyline, amoxapine, amitriptyline, clomipramine, desipramine, dosulepine, doxepin, imipramine, dibenzepin, iprindole, lofepramine, opipramol, protriptyline, and trimipramine, or pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein said co-agent is a serotonin norepinephrine reuptake inhibitor selected from the group consisting of venlafaxine, desvenlafaxine, sibutramine, nefazodone, milnacipran, duloxetine, and bicifadine, or pharmaceutically acceptable salts thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein said co-agent is a serotonin norepinephrine reuptake inhibitor selected from the group consisting of venlafaxine, desvenlafaxine, nefazodone, and duloxetine, or pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein said co-agent is a serotonin noradrenaline dopamine reuptake inhibitor selected from the group consisting of tesofensine and brasofensine, or pharmaceutically acceptable salts thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein said co-agent is a monoamine oxidase inhibitor selected from the group consisting of isocarboxazid, moclobemide, phenelzine, tranylcypromine, selegiline, rasagiline, nialamide, iproniazid, iproclozide, and toloxatone, or pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein said co-agent is a tricyclic antidepressant selected from the group consisting of butriptyline, amoxapine, amitriptyline, nortriptyline, clomipramine, desipramine, dosulepine, doxepin, imipramine, dibenzepin, iprindole, lofepramine, opipramol, protriptyline, and trimipramine, or pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein said co-agent is a tricyclic antidepressant selected from the group consisting of amitriptyline, clomipramine, desipramine, doxepin, and imipramine, or pharmaceutically acceptable salts thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein said co-agent is a selective serotonin reuptake inhibitor selected from the group consisting of fluoxetine, norfluoxetine, citalopram, dapoxetine, escitalopram, fluvoxamine, paroxetine, and sertraline, or pharmaceutically acceptable salts thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein said co-agent is a selective serotonin reuptake inhibitor selected from the group consisting of citalopram, norfluoxetine, dapoxetine, escitalopram, fluvoxamine, paroxetine, and sertraline, or pharmaceutically acceptable salts thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein said co-agent is paroxetine, or a pharmaceutically acceptable salt thereof.

### Claim 15

A method of treating pseudobulbar affect in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of a co-agent selected from the grouping consisting of citalopram, fluvoxamine, norfluoxetine, fluoxetine, paroxetine, sertraline, venlafaxine, desvenlafaxine, nefazodone, duloxetine, bupropion, moclobemide, amitriptyline, clomipramine, desipramine, doxepin, imipramine and nortriptyline, or pharmaceutically acceptable salts thereof, and a therapeutically effective amount of a compound selected from the group consisting of:
or pharmaceutically acceptable salts thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein said co-agent is citalopram, fluvoxamine, paroxetine, sertraline, venlafaxine, desvenlafaxine, nefazodone, duloxetine, bupropion, moclobemide, clomipramine, desipramine, doxepin, or imipramine, or a pharmaceutically acceptable salts thereof.

### Claim 17 (depends on 15)

The method of claim 15, wherein said co-agent is paroxetine, or a pharmaceutically acceptable salt thereof.

### Claim 18

A method of treating chronic or intractable pain in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of a co-agent selected from the grouping consisting of a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a tricyclic antidepressant; and a selective serotonin reuptake inhibitor; or pharmaceutically acceptable salts thereof; and a compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
R3 is selected from —OCH3, —OCH2D, —OCHD2, —OCD3, —OCHF2, and —OCF3; and
R4 is selected from —CH3, —CH2D, —CHD2, and —CD3;
provided that when R3 is —OCH3, then R4 is not —CH3 or —CD3;
further provided that when R3 is —OCD3, then R4 is not —CH3.

### Claim 19 (depends on 18)

The method of claim 18, wherein R4 is —CH3, —CHD2, or —CD3.

### Claim 20 (depends on 19)

The method of claim 19, wherein R3 is —OCF3, —OCD3, or —OCHF2.

### Claim 21 (depends on 18)

The method of claim 18, wherein said co-agent is an inhibitor of a cytochrome p450 2D6 enzyme.

### Claim 22 (depends on 18)

The method of claim 18, wherein said co-agent is selected from the group consisting of a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; norfluoxetine, citalopram, dapoxetine, escitalopram, fluvoxamine, paroxetine, sertraline, butriptyline, amoxapine, amitriptyline, clomipramine, desipramine, dosulepine, doxepin, imipramine, dibenzepin, iprindole, lofepramine, opipramol, protriptyline, and trimipramine, or pharmaceutically acceptable salts thereof.

### Claim 23 (depends on 18)

The method of claim 18, wherein said co-agent is a serotonin norepinephrine reuptake inhibitor selected from the group consisting of venlafaxine, desvenlafaxine, sibutramine, nefazodone, milnacipran, duloxetine, and bicifadine, or pharmaceutically acceptable salts thereof.

### Claim 24 (depends on 18)

The method of claim 18, wherein said co-agent is a serotonin norepinephrine reuptake inhibitor selected from the group consisting of venlafaxine, desvenlafaxine, nefazodone, and duloxetine, or pharmaceutically acceptable salts thereof.

### Claim 25 (depends on 18)

The method of claim 18, wherein said co-agent is a serotonin noradrenaline dopamine reuptake inhibitor selected from the group consisting of tesofensine and brasofensine, or pharmaceutically acceptable salts thereof.

### Claim 26 (depends on 18)

The method of claim 18, wherein said co-agent is a monoamine oxidase inhibitor selected from the group consisting of isocarboxazid, moclobemide, phenelzine, tranylcypromine, selegiline, rasagiline, nialamide, iproniazid, iproclozide, and toloxatone, or pharmaceutically acceptable salts thereof.

### Claim 27 (depends on 18)

The method of claim 18, wherein said co-agent is a tricyclic antidepressant selected from the group consisting of butriptyline, amoxapine, amitriptyline, nortriptyline, clomipramine, desipramine, dosulepine, doxepin, imipramine, dibenzepin, iprindole, lofepramine, opipramol, protriptyline, and trimipramine, or pharmaceutically acceptable salts thereof.

### Claim 28 (depends on 18)

The method of claim 18, wherein said co-agent is a tricyclic antidepressant selected from the group consisting of amitriptyline, clomipramine, desipramine, doxepin, and imipramine, or pharmaceutically acceptable salts thereof.

### Claim 29 (depends on 18)

The method of claim 18, wherein said co-agent is a selective serotonin reuptake inhibitor selected from the group consisting of fluoxetine, norfluoxetine, citalopram, dapoxetine, escitalopram, fluvoxamine, paroxetine, and sertraline, or pharmaceutically acceptable salts thereof.

### Claim 30 (depends on 18)

The method of claim 18, wherein said co-agent is selective serotonin reuptake inhibitor selected from the group consisting of citalopram, norfluoxetine, dapoxetine, escitalopram, fluvoxamine, paroxetine, and sertraline, or pharmaceutically acceptable salts thereof.

### Claim 31 (depends on 18)

The method of claim 18, wherein said co-agent is paroxetine, or a pharmaceutically acceptable salt thereof.

### Claim 32

A method of treating chronic or intractable pain in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of a co-agent selected from the grouping consisting of citalopram, fluvoxamine, norfluoxetine, fluoxetine, paroxetine, sertraline, venlafaxine, desvenlafaxine, nefazodone, duloxetine, bupropion, moclobemide, amitriptyline, clomipramine, desipramine, doxepin, imipramine and nortriptyline, or pharmaceutically acceptable salts thereof, and a therapeutically effective amount of a compound selected from the group consisting of:
or pharmaceutically acceptable salts thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein said co-agent is citalopram, fluvoxamine, paroxetine, sertraline, venlafaxine, desvenlafaxine, nefazodone, duloxetine, bupropion, moclobemide, clomipramine, desipramine, doxepin, or imipramine, or pharmaceutically acceptable salts thereof.

### Claim 34 (depends on 32)

The method of claim 32, wherein said co-agent is paroxetine, or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 32)

The method of claim 32, wherein said chronic or intractable pain is a neuropathic pain.

### Claim 36 (depends on 32)

The method of claim 32, wherein said chronic or intractable pain is diabetic neuropathic pain.

### Claim 37

A method of treating a neurological disorder selected from the group consisting of amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, and Huntington's disease, comprising the step of administering to said subject a therapeutically effective amount of a co-agent selected from the grouping consisting of a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a tricyclic antidepressant; and a selective serotonin reuptake inhibitor; or pharmaceutically acceptable salts thereof, and a therapeutically effective amount of a compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
R3 is selected from —OCH3, —OCH2D, —OCHD2, —OCD3, —OCHF2, and —OCF3; and
R4 is selected from —CH3, —CH2D, —CHD2, and —CD3;
provided that when R3 is —OCH3, then R4 is not —CH3 or —CD3;
further provided that when R3 is —OCD3, then R4 is not —CH3.

### Claim 38 (depends on 37)

The method of claim 37, wherein R4 is —CH3, —CHD2, or —CD3.

### Claim 39 (depends on 38)

The method of claim 38, wherein R3 is —OCF3, —OCD3, or —OCHF2.

### Claim 40 (depends on 37)

The method of claim 37, wherein said co-agent is an inhibitor of a cytochrome p450 2D6 enzyme.

### Claim 41 (depends on 37)

The method of claim 37, wherein said co-agent is selected from the group consisting of a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; norfluoxetine, citalopram, dapoxetine, escitalopram fluvoxamine, paroxetine, sertraline, butriptyline, amoxapine, nortriptyline, clomipramine, desipramine, dosulepine, doxepin, imipramine, dibenzepin, iprindole, lofepramine, opipramol, protriptyline, and trimipramine, or pharmaceutically acceptable salts thereof.

### Claim 42 (depends on 37)

The method of claim 37, wherein said co-agent is a serotonin norepinephrine reuptake inhibitor selected from the group consisting of venlafaxine, desvenlafaxine, sibutramine, nefazodone, milnacipran, duloxetine, and bicifadine, or pharmaceutically acceptable salts thereof.

### Claim 43 (depends on 37)

The method of claim 37, wherein said co-agent is a serotonin norepinephrine reuptake inhibitor selected from the group consisting of venlafaxine, desvenlafaxine, nefazodone, and duloxetine, or pharmaceutically acceptable salts thereof.

### Claim 44 (depends on 37)

The method of claim 37, wherein said co-agent is a serotonin noradrenaline dopamine reuptake inhibitor selected from the group consisting of tesofensine and brasofensine, or pharmaceutically acceptable salts thereof.

### Claim 45 (depends on 37)

The method of claim 37, wherein said co-agent is a monoamine oxidase inhibitor selected from the group consisting of isocarboxazid, moclobemide, phenelzine, tranylcypromine, selegiline, rasagiline, nialamide, iproniazid, iproclozide, and toloxatone, or pharmaceutically acceptable salts thereof.

### Claim 46 (depends on 37)

The method of claim 37, wherein said co-agent is a tricyclic antidepressant selected from the group consisting of butriptyline, amoxapine, amitriptyline, nortriptyline, clomipramine, desipramine, dosulepine, doxepin, imipramine, dibenzepin, iprindole, lofepramine, opipramol, protriptyline, and trimipramine, or pharmaceutically acceptable salts thereof.

### Claim 47 (depends on 37)

The method of claim 37, wherein said co-agent is a tricyclic antidepressant selected from the group consisting of nortriptyline, clomipramine, desipramine, doxepin, and imipramine, or pharmaceutically acceptable salts thereof.

### Claim 48 (depends on 37)

The method of claim 37, wherein said co-agent is a selective serotonin reuptake inhibitor selected from the group consisting of fluoxetine, norfluoxetine, citalopram, dapoxetine, escitalopram, fluvoxamine, paroxetine, and sertraline, or pharmaceutically acceptable salts thereof.

### Claim 49 (depends on 37)

The method of claim 37, wherein said co-agent is a selective serotonin reuptake inhibitor selected from the group consisting of citalopram, dapoxetine, escitalopram, fluvoxamine, paroxetine, and sertraline, or pharmaceutically acceptable salts thereof.

### Claim 50 (depends on 37)

The method of claim 37, wherein said co-agent is paroxetine, or a pharmaceutically acceptable salt thereof.

### Claim 51

A method of treating a neurological disorder selected from the group consisting of amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, and Huntington's disease in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of a co-agent selected from the grouping consisting of citalopram, fluvoxamine, norfluoxetine, fluoxetine, paroxetine, sertraline, venlafaxine, desvenlafaxine, nefazodone, duloxetine, bupropion, moclobemide, amitriptyline, clomipramine, desipramine, doxepin, imipramine and nortriptyline, or pharmaceutically acceptable salts thereof, and a therapeutically effective amount of a compound selected from the group consisting of:
or pharmaceutically acceptable salts thereof.

### Claim 52 (depends on 51)

The method of claim 51, wherein said co-agent is citalopram, fluvoxamine, paroxetine, sertraline, venlafaxine, desvenlafaxine, nefazodone, duloxetine, bupropion, moclobemide, clomipramine, desipramine, doxepin, or imipramine, or pharmaceutically acceptable salts thereof.

### Claim 53 (depends on 51)

The method of claim 51, wherein said co-agent is paroxetine, or a pharmaceutically acceptable salt thereof.

### Claim 54

A method of treating a brain injury that is the result of stroke, traumatic brain injury, ischemia, hypoglycemia, hypoxia, or neuronal death, comprising the step of administering to said subject a therapeutically effective amount of a co-agent selected from the grouping consisting of a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a tricyclic antidepressant; and a selective serotonin reuptake inhibitor; or a pharmaceutically acceptable salts thereof, and a therapeutically effective amount of a compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
R3 is selected from —OCH3, —OCH2D, —OCHD2, —OCD3, —OCHF2, and —OCF3; and
R4 is selected from —CH3, —CH2D, —CHD2, and —CD3;
provided that when R3 is —OCH3, then R4 is not —CH3 or —CD3:
further provided that when R3 is —OCD3, then R4 is not —CH3.

### Claim 55 (depends on 54)

The method of claim 54, wherein R4 is —CH3, —CHD2, or —CD3.

### Claim 56 (depends on 55)

The method of claim 55, wherein R3 is —OCF3, —OCD3, or —OCHF2.

### Claim 57 (depends on 54)

The method of claim 54, wherein said co-agent is an inhibitor of a cytochrome p450 2D6 enzyme.

### Claim 58 (depends on 54)

The method of claim 54, wherein said co-agent is selected from the group consisting of a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; norfluoxetine, citalopram, dapoxetine, escitalopram, fluvoxamine, paroxetine, sertraline, butriptyline, amoxapine, nortriptyline, clomipramine, desipramine, dosulepine, doxepin, imipramine, dibenzepin, iprindole, lofepramine, opipramol, protriptyline, and trimipramine, or pharmaceutically acceptable salts thereof.

### Claim 59 (depends on 54)

The method of claim 54, wherein said co-agent is a serotonin norepinephrine reuptake inhibitor selected from the group consisting of venlafaxine, desvenlafaxine, sibutramine, nefazodone, milnacipran, duloxetine, and bicifadine, or pharmaceutically acceptable salts thereof.

### Claim 60 (depends on 54)

The method of claim 54, wherein said co-agent is a serotonin norepinephrine reuptake inhibitor selected from the group consisting of venlafaxine, desvenlafaxine, nefazodone, and duloxetine, or pharmaceutically acceptable salts thereof.

### Claim 61 (depends on 54)

The method of claim 54, wherein said co-agent is a serotonin noradrenaline dopamine reuptake inhibitor selected from the group consisting of tesofensine and brasofensine, or pharmaceutically acceptable salts thereof.

### Claim 62 (depends on 54)

The method of claim 54, wherein said co-agent is a monoamine oxidase inhibitor selected from the group consisting of isocarboxazid, moclobemide, phenelzine, tranylcypromine, selegiline, rasagiline, nialamide, iproniazid, iproclozide, and toloxatone, or pharmaceutically acceptable salts thereof.

### Claim 63 (depends on 54)

The method of claim 54, wherein said co-agent is a tricyclic antidepressant selected from the group consisting of butriptyline, amoxapine, amitriptyline, nortriptyline, clomipramine, desipramine, dosulepine, doxepin, imipramine, dibenzepin, iprindole, lofepramine, opipramol, protriptyline, and trimipramine, or pharmaceutically acceptable salts thereof.

### Claim 64 (depends on 54)

The method of claim 54, wherein said co-agent is a tricyclic antidepressant selected from the group consisting of amitriptyline, nortriptyline, clomipramine, desipramine, doxepin, and imipramine, or pharmaceutically acceptable salts thereof.

### Claim 65 (depends on 54)

The method of claim 54, wherein said co-agent is a selective serotonin reuptake inhibitor selected from the group consisting of fluoxetine, norfluoxetine, citalopram, dapoxetine, escitalopram, fluvoxamine, paroxetine, and sertraline, or pharmaceutically acceptable salts thereof.

### Claim 66 (depends on 54)

The method of claim 54, wherein said co-agent is a selective serotonin reuptake inhibitor selected from the group consisting of citalopram, dapoxetine, escitalopram, fluvoxamine, paroxetine, and sertraline, or pharmaceutically acceptable salts thereof.

### Claim 67 (depends on 54)

The method of claim 54, wherein said co-agent is paroxetine, or a pharmaceutically acceptable salt thereof.

### Claim 68

A method of treating a brain injury that is the result of stroke, traumatic brain injury, ischemia, hypoglycemia, hypoxia, or neuronal death, in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of a co-agent selected from the grouping consisting of citalopram, fluvoxamine, norfluoxetine, fluoxetine, paroxetine, sertraline, venlafaxine, desvenlafaxine, nefazodone, duloxetine, bupropion, moclobemide, amitriptyline, clomipramine, desipramine, doxepin, imipramine and nortriptyline, or pharmaceutically acceptable salts thereof, and a therapeutically effective amount of a compound selected from the group consisting of:
or pharmaceutically acceptable salts thereof.

### Claim 69 (depends on 68)

The method of claim 68, wherein said co-agent is citalopram, fluvoxamine, paroxetine, sertraline, venlafaxine, desvenlafaxine, nefazodone, duloxetine, bupropion, moclobemide, clomipramine, desipramine, doxepin, or imipramine, or pharmaceutically acceptable salts thereof.

### Claim 70 (depends on 68)

The method of claim 68, wherein said co-agent is paroxetine, or a pharmaceutically acceptable salt thereof.
